未登录Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling建立一套全面的病人来源异种移植模型用于高级别子宫内膜癌：分子亚型、基因改变和治疗方法靶点分析
Sato, Sho; Yagishita, Shigehiro; Yoshida, Hiroshi; Shintani, Daisuke; Ogasawara, Aiko; Nishikawa, Tadaaki; Yasuda, Masanori; Furuuchi, Keiji; Uenaka, Toshimitsu; Hamada, Akinobu .png)
分享.png)
收藏Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer modelsFarletuzumab ecteribulin和MORAb-109，靶向叶酸受体α和间皮素的抗体-药物偶联物，在预后不良的妇科癌症模型中显示出活性。Nesic, Ksenija; Rybinski, Katherine; Ratnayake, Gayanie; Ho, Gwo-Yaw; Lim, Ratana; Radke, Marc; Neagle, Chloe; Swisher, Elizabeth M.; Wakefield, Matthew J.; Barker, Holly E.; Furuuchi, Keiji; Scott, Clare L.; Vandenberg, Cassandra J. 分享 收藏 分享 收藏 分享 收藏 Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian canceZhang, Yan; Zimmermann, Bob; Li, Shuyu; Uenaka, Toshimitsu; Furuuchi, Keiji; Yonemori, Kan; Shimizu, Toshio; Nishio, Shin; Yunokawa, Mayu; Matsumoto, Koji; Takehara, Kazuhiro; Hasegawa, Kosei; Hirashima, Yasuyuki; Kato, Hidenori; Otake, Yohei; Miura, Takuma; Matsui, Junji; Li, Meijuan 分享 收藏 Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypesHasegawa, K.; Yagishita, S.; Shintani, D.; Yoshida, H.; Suzuki, M.; Sato, S.; Ogasawara, A.; Nishikawa, T.; Yonemori, K.; Yasuda, M.; Furuuchi, K.; Uenaka, T.; Hamada, A. 分享 收藏 Preclinical development of BB-1701, a HER2-tageting eribulin-containing ADC with potent bystander effect and ICD activityWang, Yang; Xia, Bing; Cao, Lixia; Yang, Jianfeng; Feng, Cui; Jiang, Fangdun; Li, Chen; Gu, Lixia; Yang, Yifan; Tian, Jing; Cheng, Cindy; Furuuchi, Keiji; Fulmer, James; Verdi, Arielle; Rybinski, Katherine; Soto, Allis; Albone, Earl; Uenaka, Toshimitsu; Gong, Likun; Liu, Tingting; Qin, Qiuping; Wei, Ziping; Zhou, Yuhong 分享 收藏 MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBCFuruuchi, Keiji; Rybinski, Katherine; Fulmer, James; Moriyama, Tomoyuki; Drozdowski, Brian; Soto, Allis; Fernando, Shawn; Wilson, Kerrianne; Milinichik, Andrew; Dula, Mary Lou; Tanaka, Keigo; Cheng, Xin; Albone, Earl; Uenaka, Toshimitsu 分享 收藏 分享 收藏 MORAb-109: A site-specific eribulin-conjugated ADC targeting human mesothelinAlbone, E.; Cheng, X.; Verdi, A.; Jacob, S.; Fernando, S.; Furuuchi, K.; Fulmer, J.; Soto, A.; Drozdowski, B.; Mano, Y.; Nakatani, Y.; Uenaka, T. 分享 收藏 分享 收藏 MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor ActivityCheng, Xin; Li, Jing; Tanaka, Keigo; Majumder, Utpal; Milinichik, Andrew Z.; Verdi, Arielle C.; Maddage, Christopher J.; Rybinski, Katherine A.; Fernando, Shawn; Fernando, Danielle; Kuc, Megan; Furuuchi, Keiji; Fang, Frank; Uenaka, Toshimitsu; Grasso, Luigi; Albone, Earl F. 分享 收藏 MORAb-202, a folate receptor-alpha (FRA)-targeting antibody-eribulin drug conjugate (ADC), exhibits durable antitumor activity and payload-mediated bystander effects on the tumor microenvironment in triple-negative breast cancerFuruuchi, Keiji; Cheng, Xin; Rybinski, Katherine; Moriyama, Tomoyuki; Fulmer, James; Maddage, Chris; Milinichik, Andrew; Tanaka, Keigo; Lai, George; Dula, Mary Lou; Fernando, Danielle; Grasso, Luigi; Albone, Earl; Uenaka, Toshimitsu 分享 收藏 Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumorsMignard, Caroline; Durix, Coralie; Rybinski, Katherine; Cheng, Xin; Furuuchi, Keiji; Albone, Earl; Uenaka, Toshimitsu; de Boisferon, Marc Hillairet 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
